HER2-low breast cancer has changed one of the most familiar classifications in breast oncology. For many years, tumors that were not HER2-positive were generally managed as HER2-negative disease, with treatment decisions driven by hormone receptor status, prior therapy, disease tempo, and chemotherapy sensitivity. The development of trastuzumab deruxtecan has changed this framework by making low HER2 expression clinically actionable in …
Above all, love …
A family tie is like the river. It can bend, but it cannot break.” – Kwame Alexander, The Door of No Return Barbara JacobyBarbara Jacoby is an award winning blogger that has contributed her writings to multiple online publications that have touched readers worldwide. LetLifeHappen.com
Breast cancer risk assessments: What to know
By: Banu Arun, M.D. From: mdanderson.org Whatever your question, odds are there’s an online resource that promises an answer. That means it’s just as easy to search ‘What should I make for dinner?’ as it is ‘What’s my breast cancer risk?’ As a breast medical oncologist, some of the same tools my team uses to clinically assess breast cancer risk can be accessed for free online. But just like finding any cancer information …
EMA Recommends Generic for Advanced/Metastatic Breast Cancer
By: Sophie Cousins From: medscape.com The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use has recommended granting a marketing authorisation for Palbociclib Viatris (palbociclib, Viatris Limited) for the treatment of locally advanced or metastatic breast cancer. Palbociclib is a cyclin-dependent kinase 4/6 inhibitor designed to slow cancer cell proliferation for patients with hormone receptor (HR)‑positive, human epidermal …
Novel vulnerability in breast cancer brain metastases identified, pointing to new therapeutic strategy
By: Drexel University From: medicalxpress.com Researchers from Drexel University’s College of Medicine have identified a critical metabolic vulnerability in breast cancer that has spread to the brain, offering a promising new therapeutic target for a disease with few effective treatment options. When this weakness is targeted, cancer cells undergo cell death. The study found that an enzyme called acetyl-CoA synthetase …
Study uncovers potential cancer treatment that is readily available
By: Bryana Quintana From: sdsu.edu A treatment for the most common type of breast cancer may already exist. As reported in a December paper in Nature Communications, San Diego State University researchers who were part of an international study believe they found one. Associate professor of biology Svasti Haricharan initially approached her early research wondering, “Why do some people get …
A Smile Changes Everything for This Breast Cancer Survivor
View PostBreast Cancer Heterogeneity: Challenges and Therapeutic Opportunities
By: Upasana Pathak From: oncodaily.com Breast cancer is the most common cancer in women globally and shows significant heterogeneity. This heterogeneity is present at inter- and intratumoural levels and influences disease progression, therapeutic response along with clinical outcomes. Intertumoural heterogeneity arises from molecular and genomic differences in patients with distinct clinical subtypes and variable prognosis. Intratumoural heterogeneity comes from interactions …
Is Vitamin D a Key to Better Breast Cancer Survival?
By: Ernie Mundell From: medscape.com For women with breast cancer, vitamin D levels around the time of diagnosis might be related to long-term survival, a large prospective study showed. Over a median of 12 years, women with sufficient vitamin D levels at breast cancer diagnosis had a 24% boost in overall survival compared to those with a vitamin D deficiency, …
Though the fig tree does not bud …
Though the fig tree does not bud and there are no grapes on the vines, though the olive crop fails and the fields produce no food, though there are no sheep in the pen and no cattle in the stalls, yet I will rejoice in the Lord, I will be joyful in God my Savior. Habakkuk 3:17-18 Barbara JacobyBarbara Jacoby …